Preliminary results of SBRT treatment of pulmonary oligometastasis from head and neck tumors
10.3760/cma.j.cn113030-20191225-00532
- VernacularTitle:SBRT治疗头颈部肿瘤肺寡转移初步结果
- Author:
Yonghong HUA
;
Ruizeng DONG
;
Yongfeng PIAO
;
Lei WANG
;
Qiong WANG
;
Changjuan TAO
;
Yuanyuan CHEN
;
Xiaozhong CHEN
;
Qiaoying HU
;
Ming CHEN
- From:
Chinese Journal of Radiation Oncology
2021;30(3):235-238
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To preliminarily evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for pulmonary oligometastatic tumors from head and neck carcinoma.Methods:Clinical data of 24 patients with pulmonary oligometastasis from head and neck carcinoma undergoing SBRT in Zhejiang Cancer Hospital from January 2014 to May 2019 were retrospectively analyzed. Survival analysis was performed by Kaplan- Meier method. Results:Among the 24 patients, 12 cases were diagnosed with nasopharyngeal origin and 12 cases of non-nasopharyngeal origin. A total of 34 pulmonary metastatic lesions were treated with SBRT. The median follow-up time was 19.5 months. Thirteen cases developed new lesions after SBRT, and 9 of them occurred within 1 year after SBRT treatment. The actual 1-year local control rate was 95%. The median progression-free survival was 15.2 months, and the 1-and 2-year progression-free survival were 59% and 46%, respectively. The 2-and 3-years overall survival rate at were 71% and 51% fter lung metastasis, respectively. Univariate analysis showed that the patients with primary lesions located in nasopharynx and disease-free interval of more than 1 year had survival advantage. No more than grade 3 radiation-induced injury was observed in the whole cohort after SBRT, and the incidence of mild radiation-induced injury was 13%.Conclusions:SBRT is safe and effective in the treatment of pulmonary oligometastatsis from head and neck carcinoma, and it may be more effective for patients with primary tumors located in nasopharynx.
